The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., & Riccardi, C. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90198-o · Cited by 4,579
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Self-citationTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Self-citationSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Self-citationInduction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Self-citationApoptosis control by death and decoy receptors
Ashkenazi, A., & Dixit, V. M. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80034-9 · Cited by 1,288
Self-citationApo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Self-citationJo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Self-citationSchneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., & Rehemtulla, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.030545097 · Cited by 530
Cited by
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Self-citationOverview of cell death signaling pathways
Jin, Z., & El-Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1508 · Cited by 1,326
The molecular architecture of the TNF superfamily
Bodmer, J.-L., Schneider, P., & Tschopp, J. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01995-8 · Cited by 916
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Self-citationThe TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Fulda, S., Wick, W., Weller, M., & Debatin, K.-M. (2002) · Nature Medicine · doi:10.1038/nm735 · Cited by 741
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
Zhang, L., & Fang, B. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700792 · Cited by 702
Apoptosis: a basic biological phenomenon with wide‐ranging implications in human disease
FADEEL, B., & ORRENIUS, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 698
Life and death by death receptors
Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 690
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 553
Self-citationTumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507
Self-citationDeath receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446
Self-citationKelley, S. K., Harris, L. A., Xie, D., DeForge, L., Totpal, K., Bussiere, J., & Fox, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 445
Self-citationNatural Killer Cells and Cancer
(2003) · Advances in Cancer Research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 438
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Self-citationAshkenazi, A., Holland, P., & Eckhardt, S. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7198 · Cited by 421
Self-citationDunn, C., Brunetto, M., Reynolds, G., Christophides, T., Kennedy, P. T., Lampertico, P., Das, A., Lopes, A. R., Borrow, P., Williams, K., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061287 · Cited by 421
Targeting the extrinsic apoptosis pathway in cancer
Ashkenazi, A. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.04.001 · Cited by 418
Self-citationMesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
Fulda, S., Meyer, E., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205258 · Cited by 394
Targeting death receptors in cancer with Apo2L/TRAIL
KELLEY, S. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.006 · Cited by 370
Self-citationNature's TRAIL—On a Path to Cancer Immunotherapy
Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R. M., & Yagita, H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00502-2 · Cited by 366
New insights into apoptosis signaling by Apo2L/TRAIL
Gonzalvez, F., & Ashkenazi, A. (2010) · Oncogene · doi:10.1038/onc.2010.221 · Cited by 359
Self-citationTo kill a tumor cell: the potential of proapoptotic receptor agonists
Ashkenazi, A., & Herbst, R. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34359 · Cited by 323
Self-citationTolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Kim, Y., Suh, N., Sporn, M., & Reed, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202458200 · Cited by 309
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 305
Onto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 301
Cell surface Death Receptor signaling in normal and cancer cells
Özören, N., & El-Deiry, W. S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00131-1 · Cited by 289
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284
Self-citationApoptosis-based therapies and drug targets
Fischer, U., & Schulze-Osthoff, K. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401556 · Cited by 282
TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer
Srivastava, R. K. (2001) · Neoplasia · doi:10.1038/sj.neo.7900203 · Cited by 280
Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L. (2013) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 276
Regulated Cell Death: Signaling and Mechanisms
Ashkenazi, A., & Salvesen, G. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013226 · Cited by 274
Self-citationTRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam, D., Szegezdi, E., Keane, M., Jong, S. D., & Samali, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 272
Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., & Sakai, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207830 · Cited by 271
New Approaches and Therapeutics Targeting Apoptosis in Disease
Fischer, U., & Schulze-Osthoff, K. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.6 · Cited by 257
TRAIL and its receptors as targets for cancer therapy
Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M. J., & Okumura, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02181.x · Cited by 254
Death receptors as targets in cancer
Micheau, O., Shirley, S., & Dufour, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12238 · Cited by 189
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802702105 · Cited by 148
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
Self-citationEvdokiou, A., Bouralexis, S., Atkins, G. J., Chai, F., Hay, S., Clayer, M., & Findlay, D. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10376 · Cited by 129
Kaplan-Lefko, P. J., Graves, J. D., Zoog, S. J., Pan, Y., Wall, J., Branstetter, D. G., Moriguchi, J., Coxon, A., Huard, J. N., Xu, R., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11264 · Cited by 126
Self-citationCorazza, N., Jakob, S., Schaer, C., Frese, S., Keogh, A., Stroka, D., Kassahn, D., Torgler, R., Mueller, C., Schneider, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27726 · Cited by 123
Gamie, Z., Kapriniotis, K., Papanikolaou, D., Haagensen, E., Da Conceicao Ribeiro, R., Dalgarno, K., Krippner-Heidenreich, A., Gerrand, C., Tsiridis, E., & Rankin, K. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.036 · Cited by 44
Metadata
- Authors
- Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A., Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., & Ashkenazi, A.
- Venue
- Nature Medicine
- Published
- 2001-04
- Volume
- 7
- Issue
- 4
- Pages
- 383-385
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2119326933
- Cited by
- 702
- References
- 16
- FWCI
- 20.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.